Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 19:54:44时区推断·⟳ 抓取 19:56:18·⚡ 决策 07-22 20:03:16 +6m58s·97.0 天前
Arrowhead披露plozasiran两项3期SHASTA研究达到主要和次要终点
SHASTA-3/4显示plozasiran在重度高甘油三酯血症患者中12个月甘油三酯中位降幅79%/81%，且急性胰腺炎事件率合并分析显著下降。
📄 原文Investing.com↗ 原文
Arrowhead Pharmaceuticals stock jumps on Phase 3 trial results
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven? Investing.com -- Arrowhead Pharmaceutical…
不做 Arrowhead Pharmaceuticals（ARWR.US）
3期顶线成功是正面进展，但正文已显示股价因消息大幅反应，且扩适应症仍需年底前提交sNDA、短期收入未落地，当前不追多。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 medium · price-in 风险 high ↗
消息传播链
- 报道披露SHASTA-3/4顶线结果及股价已大幅上涨，说明事件已进入公开传播和市场反应阶段。市场反应:正文称ARWR股价一度上涨18%；工具取到最新价74.52美元，较前收上涨4.01%。
关键理由
- SHASTA-3/4显示plozasiran在重度高甘油三酯血症患者中12个月甘油三酯中位降幅79%/81%，且急性胰腺炎事件率合并分析显著下降。
- 事件仍处于补充NDA计划阶段，公司称拟在2026年底前向FDA提交，短期商业收入增量尚未落地。
- Arrowhead（ARWR.US）最新总市值约105亿美元，本次扩适应症潜在市场较大但当前只有顶线数据，需等待详细数据和监管受理。
主要风险
- Investing.com正文称股价已因该消息一度上涨18%，工具取到最新价74.52美元、较前收仍涨4.01%，短线追价的剩余edge不足。
- 同赛道仍有竞争药物和监管审评不确定性，且内部KB未命中可验证的产品销售量级片段。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中与本药物量级或反向风险直接相关的有效片段，不能补强商业化量级。
检索:Arrowhead plozasiran severe hypertriglyceridemia SHASTA Phase 3 competition olezarsen - 做多前查反向 · 来源 web · 影响 weakens
做多前关注竞品和监管审评风险；当前未发现足以推翻顶线数据正向性的公开反证。
检索:Arrowhead Pharmaceuticals recent risks plozasiran competition olezarsen
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,622 字
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
Investing.com -- Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares rose 18% Wednesday following the announcement of topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridemia.
The studies met their primary endpoint of triglyceride reduction versus placebo and all prespecified secondary endpoints. Plozasiran, administered as a 25 mg subcutaneous injection once every three months, led to median triglyceride reductions of 79% and 81% at month 12 in SHASTA-3 and SHASTA-4, respectively, compared to approximately 27% reduction with placebo.
A pre-planned pooled analysis of acute pancreatitis events across both studies showed a statistically significant reduction in event rates compared to placebo. The drug demonstrated a favorable safety and tolerability profile with no new safety signals and no clinically meaningful differences in routine clinical laboratory measurements.
Plozasiran has received regulatory approval as REDEMPLO in the United States, European Union, China, Australia, and Canada for treating adults with familial chylomicronemia syndrome. The company plans to file a supplemental new drug application with the U.S. FDA before the end of 2026 to expand the drug’s indication to severe hypertriglyceridemia.
Detailed results from SHASTA-3 and SHASTA-4 will be presented at the European Society of Cardiology Congress in Munich on August 30, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Investing.com -- Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares rose 18% Wednesday following the announcement of topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridemia.
The studies met their primary endpoint of triglyceride reduction versus placebo and all prespecified secondary endpoints. Plozasiran, administered as a 25 mg subcutaneous injection once every three months, led to median triglyceride reductions of 79% and 81% at month 12 in SHASTA-3 and SHASTA-4, respectively, compared to approximately 27% reduction with placebo.
A pre-planned pooled analysis of acute pancreatitis events across both studies showed a statistically significant reduction in event rates compared to placebo. The drug demonstrated a favorable safety and tolerability profile with no new safety signals and no clinically meaningful differences in routine clinical laboratory measurements.
Plozasiran has received regulatory approval as REDEMPLO in the United States, European Union, China, Australia, and Canada for treating adults with familial chylomicronemia syndrome. The company plans to file a supplemental new drug application with the U.S. FDA before the end of 2026 to expand the drug’s indication to severe hypertriglyceridemia.
Detailed results from SHASTA-3 and SHASTA-4 will be presented at the European Society of Cardiology Congress in Munich on August 30, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。